Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Endonovo Therapeutics Inc

Market Cap 2.77M 2.39M 2.2M 2.07M 3.89M 262M 3.92M 26.07M 10.15M 128M 10.41M 10.19M 444M P/E 2021
-0.3x
P/E 2022 -0.14x
Enterprise Value 9.93M 8.56M 7.87M 7.41M 13.92M 937M 14.04M 93.3M 36.32M 460M 37.26M 36.46M 1.59B EV / Sales 2021
112,421,804x
EV / Sales 2022 78,689,579x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 61 2012-02-29
Investor Relations Contact - 2014-04-30
Corporate Officer/Principal 77 2022-11-29
Director TitleAgeSince
Chairman 61 2012-02-29
Change 5-day change 1-year change 3-year change Capi.($)
+3.23%+2.25%+65.02%+113.87% 54.54B
+0.04%+1.20%+47.67%+36.75% 43.86B
+3.04%+7.05%-12.15%-18.06% 22.63B
+3.07%+7.15%-1.82%+392.25% 20.7B
+0.20%+0.33%+20.89%-35.67% 15.84B
+5.27%+1.87%+13.67%-38.81% 14.83B
+0.65%-0.27%+26.80%+174.70% 13.1B
-0.59%+2.03%+17.45% - 12.66B
+1.92%+2.43%+112.68%+232.59% 11.68B
Average +1.95%+2.14%+32.25%+107.20% 23.31B
Weighted average by Cap. +2.03%+2.15%+36.91%+98.38%

Financials

2021 2022
Net sales 0.07 0.06 0.06 0.05 0.1 6.9 0.1 0.69 0.27 3.39 0.27 0.27 11.71 0.14 0.12 0.11 0.1 0.19 12.77 0.19 1.27 0.5 6.27 0.51 0.5 21.69
Net income -3.1M -2.68M -2.46M -2.32M -4.36M -293M -4.39M -29.18M -11.36M -144M -11.65M -11.4M -498M -18.47M -15.94M -14.65M -13.79M -25.92M -1.74B -26.13M -174M -67.61M -856M -69.34M -67.86M -2.96B
Net Debt 7.1M 6.12M 5.63M 5.3M 9.95M 670M 10.04M 66.69M 25.96M 329M 26.63M 26.06M 1.14B 7.15M 6.17M 5.67M 5.34M 10.03M 675M 10.12M 67.24M 26.18M 331M 26.85M 26.27M 1.15B
Logo Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at approximately 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!